Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 124

Sort by

Sort Order Select

Journal Articles

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Blood (2025) 146 (23): 2758–2764.

https://doi.org/10.1182/blood.2025028823

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of MYC alterations in de novo large B-cell lymphoma: An italian single center experience

Chiara Pagani, Alessandro Re, Angela Passi, Rosa Daffini, Francesca Schieppati, Antonella Anastasia, Marina Motta, Ester Lovato, Chiara Cattaneo, Simone Maifredi, Alessia Pantaleo, Luisa Lorenzi, Piera Balzarini, Alessandra Tucci

Blood (2025) 146 (Supplement 1): 5443.

https://doi.org/10.1182/blood-2025-5443

Published: 2025

Journal Articles

Increased incidence of secondary malignancies after autologous stem cell transplantation in follicular lymphoma patients: Long-term results of the FIL-FLAZ12 Phase III randomized trial

Blood (2025) 146 (Supplement 1): 5364.

https://doi.org/10.1182/blood-2025-5364

Published: 2025

Journal Articles

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

Blood (2025) 146 (Supplement 1): 466.

https://doi.org/10.1182/blood-2025-466

Published: 2025

Journal Articles

Phase 2 bellwave-003 cohort f: Updated clinical outcomes of nemtabrutinib in participants with relapsed or refractory marginal zone lymphoma

Alessandra Tucci, Yair Herishanu, Juan Dupont, Sarit Assouline, Lori Leslie, Thor Hoyer, Pier Luigi Zinzani, Yan Xu, Mohammed Z.H. Farooqui, Jing Yang, Muhit Ozcan

Blood (2025) 146 (Supplement 1): 1801.

https://doi.org/10.1182/blood-2025-1801

Published: 2025

Journal Articles

Lessons from the IELSG45 trial: The impact of patient fitness on dropout rate in primary central nervous system lymphoma (PCNSL) studies

Blood (2025) 146 (Supplement 1): 1908.

https://doi.org/10.1182/blood-2025-1908

Published: 2025

Journal Articles

Low vitamin d is an unmodifiable adverse prognostic factor in older DLBCL patients: Results from the previd randomized trial by fondazione italiana linfomi (FIL).

Blood (2025) 146 (Supplement 1): 5462.

https://doi.org/10.1182/blood-2025-5462

Published: 2025

Journal Articles

Reassessing ASCT in patients aged 65–75 with multiple myeloma in the era of anti-CD38 therapies

Angelo Belotti, Paola Maestri, Sofia Terlizzi, Rossella Ribolla, Claudia Crippa, Samantha Ferrari, Nicola Bianchetti, Chiara Bottelli, Chiara Cattaneo, Marco Chiarini, Viviana Giustini, Michele Malagola, Aldo Roccaro, Alessandra Tucci

Blood (2025) 146 (Supplement 1): 4040.

https://doi.org/10.1182/blood-2025-4040

Published: 2025

Journal Articles

Elderly Acute Myeloid Leukemia (AML) with NPM1 or FLT3-ITD mutated: Is venetoclax the game changer also in fit patients? a real-life retrospective analysis by the rete ematologica lombarda

Blood (2025) 146 (Supplement 1): 3438.

https://doi.org/10.1182/blood-2025-3438

Published: 2025

Journal Articles

Infectious complications in elderly newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents with or without venetoclax: Comparison with a historical control group treated with intensive chemotherapy

Chiara Cattaneo, Lisa Colleoni, Mirko Farina, Laura Donatoni, Lorenzo Masina, Simone Maifredi, Erika Borlenghi, Francesca Federico, Alessandra Tucci, Michele Malagola

Blood (2025) 146 (Supplement 1): 6895.

https://doi.org/10.1182/blood-2025-6895

Published: 2025

Journal Articles

Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)

Blood (2024) 144 (Supplement 1): 2863.

https://doi.org/10.1182/blood-2024-202530

Published: 2024

Journal Articles

How Many Chronic Myeloid Leukemia (CML) Patients in Chronic Phase (CP) Benefit from Treatment Free Remission? a Single Center Real-Life Experience

Mariella D'Adda, Valeria Cancelli, Sofia Terlizzi, Annamaria Pelizzari, Samantha Ferrari, Diego Bertoli, Chiara Bottelli, Nicola Bianchetti, Annalisa Peli, Ilaria Accarino, Carlotta Giupponi, Alessandra Tucci

Blood (2024) 144 (Supplement 1): 6612.

https://doi.org/10.1182/blood-2024-210714

Published: 2024

Journal Articles

Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy - MCL Elderly III

Stephanie Herold, Anke Ohler, Marie-Kristin Tilch, Christian Schmidt, Michael Unterhalt, Eva Hoster, Elisabeth Hoenig, Susanne Singer, Carlo Visco, Marco Ladetto, Alessandra Tucci, Christiane Pott, Georg Hess, Martin Dreyling

Blood (2024) 144 (Supplement 1): 3042.2.

https://doi.org/10.1182/blood-2024-204691

Published: 2024

Journal Articles

A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma

Swaminathan P Iyer, Ranjit Nair, Neha Mehta-Shah, Don A. Stevens, Alessandra Tucci, Antonio Pinto, Pier Luigi Zinzani

Blood (2024) 144 (Supplement 1): 4449.

https://doi.org/10.1182/blood-2024-209340

Published: 2024

Journal Articles

Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results

Blood (2024) 144 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2024-204659

Published: 2024

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2024) 144 (Supplement 1): 3070.

https://doi.org/10.1182/blood-2024-207545

Published: 2024

Journal Articles

Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score

Angelo Belotti, Barbara Frittoli, Sofia Terlizzi, Rossella Ribolla, Claudia Crippa, Chiara Saeli, Samantha Ferrari, Annalisa Peli, Nicola Bianchetti, Chiara Bottelli, Chiara Cattaneo, Carmela Carbone, Alessandro Gullino, Marco Chiarini, Viviana Giustini, Aldo Roccaro, Luigi Grazioli, Alessandra Tucci

Blood (2024) 144 (Supplement 1): 82.

https://doi.org/10.1182/blood-2024-198779

Published: 2024

Journal Articles

B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements

Blood (2024) 144 (Supplement 1): 453.

https://doi.org/10.1182/blood-2024-203258

Published: 2024

Journal Articles

Impact of Infectious Complications Should be Considered When Choosing Chemotherapy for Elderly Acute Myeloid Leukemia Fit Patients: Results of a Large Monocentric Retrospective Study

Erika Borlenghi, Erika Borlenghi, Irene Terrenato, Margherita Oberti, Giulia Soverini, Angelica Spolzino, Elisa Cerqui, Simone Maifredi, Ester Lovato, Lorenzo Masina, Francesca Federico, Diego Bertoli, Francesco Marchesi, Giuseppe Rossi, Alessandra Tucci

Blood (2024) 144 (Supplement 1): 5946.

https://doi.org/10.1182/blood-2024-203868

Published: 2024

Journal Articles

Impact of MYC Alterations in De Novo and Transformed Large B-Cell Lymphoma: An Italian Single Center Experience

Chiara Pagani, Alessandro Re, Simone Maifredi, Angela Passi, Rosa Daffini, Antonella Anastasia, Marina Motta, Samuele Bagnasco, Erika Borlenghi, Alessia Pantaleo, Chiara Aquilina, Alessandra Tucci

Blood (2024) 144 (Supplement 1): 4473.

https://doi.org/10.1182/blood-2024-208478

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Impact of MYC alterations in de novo large B-cell lymphoma: An italian single center experience

Increased incidence of secondary malignancies after autologous stem cell transplantation in follicular lymphoma patients: Long-term results of the FIL-FLAZ12 Phase III randomized trial

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

Phase 2 bellwave-003 cohort f: Updated clinical outcomes of nemtabrutinib in participants with relapsed or refractory marginal zone lymphoma

Lessons from the IELSG45 trial: The impact of patient fitness on dropout rate in primary central nervous system lymphoma (PCNSL) studies

Low vitamin d is an unmodifiable adverse prognostic factor in older DLBCL patients: Results from the previd randomized trial by fondazione italiana linfomi (FIL).

Reassessing ASCT in patients aged 65–75 with multiple myeloma in the era of anti-CD38 therapies

Elderly Acute Myeloid Leukemia (AML) with NPM1 or FLT3-ITD mutated: Is venetoclax the game changer also in fit patients? a real-life retrospective analysis by the rete ematologica lombarda

Infectious complications in elderly newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents with or without venetoclax: Comparison with a historical control group treated with intensive chemotherapy

How Many Chronic Myeloid Leukemia (CML) Patients in Chronic Phase (CP) Benefit from Treatment Free Remission? a Single Center Real-Life Experience

Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy - MCL Elderly III

A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma

Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results

Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score

B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements

Impact of Infectious Complications Should be Considered When Choosing Chemotherapy for Elderly Acute Myeloid Leukemia Fit Patients: Results of a Large Monocentric Retrospective Study

Impact of MYC Alterations in De Novo and Transformed Large B-Cell Lymphoma: An Italian Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only